Loading...

News List

罗氏公司发布最新临床数据,单抗药物可持续减缓帕金森病进展

2024-10-19


近日,罗氏公司(Roche)的研究人员在国际顶尖医学期刊 Nature Medicine 上发表了题为:Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial 的研究论文。

该研究揭示了靶向α-突触核蛋白(α-Syn)的单克隆抗体Prasinezumab在PASADENA临床试验的开放标签扩展研究中的数据,显示Prasinezumab对帕金森病患者的运动进展有长期持续作用。


Pre: Copd lung disease breakthrough! Successful Phase III study of GSK Mepolizumab

Next: Roche has released new clinical data showing that monoclonal antibodies sustainably slow the progression of Parkinson's disease

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.